With 4.5% CAGR, Rubella Diagnostic Testing Market Size Worth US$ 6.97 billion by 2030, Growth Plus Reports

News provided by

Sep 19, 2022, 09:20 ET

NEW YORK, Sept. 19, 2022 /PRNewswire/ -- According to the latest report published by growth plus reports, the global rubella diagnostic testing market is expected to clock US$ 6.97 billion by 2030 and to grow at a CAGR of 4.5% during the forecast period. Owing to the increased prevalence of chronic diseases and various programs launched by the government refilling the market growth. This exclusive information is published by Growth Plus Reports in its report titled "Rubella Diagnostic Testing Market – Global Outlook & Forecast 2022-2030".

Request a Sample Copy of the Research Report: https://growthplusreports.com/report/rubella-diagnostic-testing-market/7812

Market Drivers

The increased prevalence of chronic diseases brought on by the togavirus is anticipated to propel the global market for rubella diagnostic testing to considerable growth over the forecast period. A direct result of togavirus's strong airborne transmission capacity is an increase in rubella cases. Children and adults are typically affected by rubella infection. The virus has severe effects on expectant mothers and may result in foetal mortality or congenital abnormalities. In addition, laboratories are fuelling the expansion of the global market for rubella diagnostic tests. Various government programmes including the research and development of new diagnostic techniques are being carried out in rising nations such as China and India in an effort to combat rubella illness, which is projected to stimulate market growth in the near future.

Excerpts from 'By Testing Techniques Segmentation'

Based on testing techniques the global rubella diagnostic testing has been segmented into

Latex Agglutination
Enzyme Immunoassay (Eia)
Radioimmunoassay (Ria)
Fluorescent Immunoassay (Fia)
Other Testing Techniques

Due to the advantages of the enzyme immunoassay (EIA) method and the rising rates of rubella, the enzyme immunoassay (EIA) is anticipated to hold the largest market share over the projection period. The enzyme immunoassay is the most popular because it is technically simple to use, fast, and extremely sensitive. Immunoglobulin G (IgG) antibodies specific for rubella are found using EIA. The most often used method when using commercial enzyme immunoassay (EIA) kits is IgM testing. The rubella virus can persist in the bloodstream for years before being killed by antibodies produced by the immune system. Since a significant increase in antibody levels was found in all matched specimens tested from patients with acute rubella infection, the EIA is also useful for identifying acute infections.

Inquiry Before Buying: https://growthplusreports.com/inquiry/before-buying/rubella-diagnostic-testing-market/7812

Excerpts from 'By Region Segmentation'

Based on region, the global rubella diagnostic testing has been segmented into:

North America
Europe
Asia Pacific
Rest of the World

The Middle East and Africa are anticipated to dominate the global market for rubella diagnostic testing over the projected period (2022-2029) owing to the growing prevalence of rubella virus infection. For instance, according to the WHO, Africa had a high number of cases in 2020—4887—compared to other WHO regions. Additionally, these regions' poor immunisation outcomes will contribute to their domination in approaching predicted years. According to the WHO regional office for Africa, the African Region continues to lag behind other WHO regions of the world in terms of access to immunisation; approximately 1 in 5 African children do not receive all of the required and basic immunizations; as a result, more than 30 million African children under the age of five continue to suffer from vaccine-preventable diseases (VPDs) each year in Africa, and more than half a million children die from these diseases each year, accounting for approximately 5% of all child. However, geographically, the rubella diagnostic testing market was found to develop at the fastest rate in the Asia-Pacific region. Over the course of the projection period, it is anticipated that this trend would continue without experiencing any notable changes. Due to greater untapped potential, a lack of awareness in some countries, and government efforts to reduce illness incidence, the Asia-Pacific region has the largest market share.

Excerpts from 'Competitive Landscape'

Some of the prominent market players in the global rubella diagnostic testing include

Ortho Clinical Diagnostics
Abbott Laboratories Merck & Co
Siemens AG
GlaxoSmithKline plc
Hoffmann La Roche Ltd
Bio Rad Laboratories, Inc
BioMerieux SA
Beckman Coulter Inc
Thermo Fisher Scientific Inc
Johnson & Johnson Diagnostics, Inc
Zenith Healthcare Ltd
Novartis Diagnostics
ZEUS Scientific Inc
Biokit SA

Table of Content

INTRODUCTION

Market Ecosystem
Timeline Under Consideration

Historical Years - 2020
Base Years - 2021
Forecasted Years – 2022 to 2030

Currency Used in the Report

RESEARCH METHODOLOGY

Research Approach
Data Collection Methodology
Data Sources

Secondary Sources
Primary Sources

Market Estimation Approach

Bottom Up
Top Down

Market Forecasting Model
Limitations and Assumptions

PREMIUM INSIGHTS

Current Market Trend (COVID-19 Perspective)
Key Players & Competitive Positioning (2021)

MARKET DYNAMICS

Drivers
Restraints/Challenges
Opportunities

GLOBAL RUBELLA DIAGNOSTIC TESTING MARKET - ANALYSIS & FORECAST, BY TESTING TECHNIQUES

Latex Agglutination
Enzyme Immunoassay (EIA)
Radioimmunoassay (RIA),
Fluorescent Immunoassay (FIA)
Other

GLOBAL RUBELLA DIAGNOSTIC TESTING MARKET - ANALYSIS & FORECAST, BY APPLICATION

Hospital
Laboratories
Others

VALUE PROPOSITIONS RELATED TO THE REPORT:

Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
Comprehensive quantitative and qualitative insights at segment and sub-segment level
Covid 19 impact trends and perspective
Granular insights at global/regional/country level
Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
Blanket coverage on competitive landscape
Winning imperatives
Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

CUSTOMIZATION OPTIONS:

Distributor Landscape Assessment
Pricing Intelligence
Customer Base Assessment
Investment & Initiatives Analysis
'Business Profile' of Key Players

Directly Purchase a Premium Copy of Rubella Diagnostic Testing Market Growth Report (2022-2030) at: https://growthplusreports.com/checkout?_token=YCOkO2fUcBz68MmnvB9ARqxIJ7GZlnaa1dmaD6ze&report_id=7812&license=Single

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.

Contact:
Manan Sethi
Director, Market Insights
Email: [email protected]
Phone no: +91 96545 76783
Web: https://growthplusreports.com/
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/1671244/Growth_Plus_Reports_Logo.jpg

SOURCE Growth Plus Reports